Patients with NASH have been enrolled in 3 phase III trials of Saroglitazar, says Zydus Cadila

"Patients with NASH have been enrolled in these trials across clinical sites in India and Mexico," Cadila Healthcare, the listed entity of the group, said in a BSE filing.

New Delhi: Zydus Cadila Thursday said it has completed enrollment of patients in three phase III trials of Magnesium for Non-Alcoholic SteatoHepatitis (NASH), a progressive disease of the liver.

"Patients with NASH have been enrolled in these trials across clinical sites in India and Mexico," Cadila Healthcare, the listed entity of the group, said in a BSE filing.

Also Read: Zydus Cadila gets USFDA nod for generic Misoprostol tablets to treat ulcers

"We are excited about the progress that Saroglitazar Mg has been making in the NASH trials. It is currently being evaluated in over 23 different controlled clinical trials, involving over 3,800 patients," Zydus Group Chairman Pankaj R Patel said in BSE filing.

Also Read: Zydus Announces Completion of Enrolment in EVIDENCES IV Phase 2 Clinical Trial of Saroglitazar Magnesium in NASH